Jean-Pierre Allam

TL;DR: Best evidence of the clinical efficacy of novel immunologic approaches using biological agents in patients with AD is available for the anti-IL-4 receptor α-chain antibody dupilumab, but a number of studies are currently ongoing with other specific antagonists to immune system players.

TL;DR: Way in which novel nonparenteral approaches for immune intervention, such as allergen-specific immunotherapy applied by way of the sublingual route, might be improved to target the tolerogenic properties of the sophisticated oral mucosal immune network.

TL;DR: OLC showed a higher allogeneic stimulatory activity than sLC, whereas the activation of autologous T cells correlated to the FcepsilonRI expression, indicating that oLC profoundly differ from their skin counterparts.

TL;DR: TLR4-ligation on oLCs might not only play a role in pathogen recognition for efficient immunity but also contribute to the tolerogenic state predominating in the oral cavity.

TL;DR: It is concluded that FcepsilonRI-bearing pDCs from patients with AD are different from p DCs of healthy individuals, might be important in the pathophysiology of AD, and contribute to the enhanced susceptibility of patients withAD to viral infections.